Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.

Humans Nivolumab / therapeutic use Stomach Neoplasms / drug therapy Ligands Biomarkers, Tumor Prognosis Apoptosis B7-H1 Antigen / metabolism
Gastric cancer Nivolumab Soluble CTLA-4 Soluble PD-1 Soluble PD-L1

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
05 2023
Historique:
received: 21 10 2022
revised: 24 01 2023
accepted: 02 02 2023
medline: 17 4 2023
pubmed: 9 3 2023
entrez: 8 3 2023
Statut: ppublish

Résumé

The clinical value of soluble forms of programmed cell death-1 (sPD-1), PD ligand 1 (sPD-L1) and cytotoxic T lymphocyte-associated protein-4 (sCTLA-4) for gastric cancer (GC) patients treated with nivolumab monotherapy has remained unknown. Blood samples collected before nivolumab treatment from 439 GC patients enrolled in the DELIVER (Japan Clinical Cancer Research Organisation GC-08) trial were analysed for sPD-1, sPD-L1 and sCTLA-4. Corresponding baseline clinical data were also retrieved. Higher plasma levels of sPD-1 (hazard ratio [HR] = 1.27, p = 0.020), sPD-L1 (HR = 1.86, p < 0.001) and sCTLA-4 (HR = 1.33, p = 0.008) were significantly associated with shorter overall survival (OS), whereas only higher sPD-L1 levels was significantly associated with shorter progression-free survival (HR = 1.30, p = 0.008). The sPD-L1 concentration was significantly associated with the Glasgow prognostic score (GPS) (p < 0.001), but both sPD-L1 (HR = 1.67, p < 0.001) and GPS (HR = 1.39, p = 0.009 for GPS 0 versus 1; HR = 1.95, p < 0.001 for GPS 0 versus 2) were independently associated with OS. Patients with a GPS of 0 and low sPD-L1 thus showed the longest OS (median, 12.0 months) and those with a GPS of 2 and high sPD-L1 showed the shortest OS (median, 3.1 months), yielding a HR of 3.69 (p < 0.001). Baseline sPD-L1 levels have the potential to predict survival for advanced GC patients treated with nivolumab, with the prognostic accuracy of sPD-L1 being improved by its combination with GPS.

Sections du résumé

BACKGROUND
The clinical value of soluble forms of programmed cell death-1 (sPD-1), PD ligand 1 (sPD-L1) and cytotoxic T lymphocyte-associated protein-4 (sCTLA-4) for gastric cancer (GC) patients treated with nivolumab monotherapy has remained unknown.
METHODS
Blood samples collected before nivolumab treatment from 439 GC patients enrolled in the DELIVER (Japan Clinical Cancer Research Organisation GC-08) trial were analysed for sPD-1, sPD-L1 and sCTLA-4. Corresponding baseline clinical data were also retrieved.
RESULTS
Higher plasma levels of sPD-1 (hazard ratio [HR] = 1.27, p = 0.020), sPD-L1 (HR = 1.86, p < 0.001) and sCTLA-4 (HR = 1.33, p = 0.008) were significantly associated with shorter overall survival (OS), whereas only higher sPD-L1 levels was significantly associated with shorter progression-free survival (HR = 1.30, p = 0.008). The sPD-L1 concentration was significantly associated with the Glasgow prognostic score (GPS) (p < 0.001), but both sPD-L1 (HR = 1.67, p < 0.001) and GPS (HR = 1.39, p = 0.009 for GPS 0 versus 1; HR = 1.95, p < 0.001 for GPS 0 versus 2) were independently associated with OS. Patients with a GPS of 0 and low sPD-L1 thus showed the longest OS (median, 12.0 months) and those with a GPS of 2 and high sPD-L1 showed the shortest OS (median, 3.1 months), yielding a HR of 3.69 (p < 0.001).
CONCLUSION
Baseline sPD-L1 levels have the potential to predict survival for advanced GC patients treated with nivolumab, with the prognostic accuracy of sPD-L1 being improved by its combination with GPS.

Identifiants

DOI: 10.1016/j.ejca.2023.02.003 PMID: 36889037
pubmed: 36889037
pii: S0959-8049(23)00064-3
doi: 10.1016/j.ejca.2023.02.003
pii:
doi:

Substances chimiques

Nivolumab 31YO63LBSN
Ligands 0
Biomarkers, Tumor 0
B7-H1 Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10-20

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement H. Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; lecture fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; and research funding from Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Eisai Co. Ltd. Y. Sunakawa has received consulting fees from Ono Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd, and Guardant Health Japan Co.; honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd, Guardant Health Japan Co., Sysmex Co., and Taiho Pharmaceutical Co. Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Sanofi, Taiho Pharmaceutical Co. Ltd., and Ohtsuka Pharmaceutical Co. E. Inoue has received consulting fees from Nippontect Systems Co. Ltd. as well as lecture fees from Bristol-Myers Squibb Co. Ltd. and Pfizer Japan Inc. K. R. Matoba is a director of the DNA Chip Research Inc. and holds shares in the company. Noda, T. Sato, C. Suminaka, and M. Yamaki are employees of Sysmex Corporation. Y. Sakamoto has received lecture fees from Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Honsha Co. Ltd. Y. Kito has received honoraria from Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd. A. Makiyama has received honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. H Hayashi has received honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Kyorin Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., MSD K.K., Novartis Pharmaceuticals K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; consulting fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Shanghai Haihe Biopharma, Takeda Pharmaceutical Co. Ltd., and Merck Biopharma Co. Ltd.; and research funding from AstraZeneca K.K., Astellas Pharma, MSD K.K., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., grants, Pfizer Japan Inc., Bristol Myers Squibb Company, Eli Lilly Japan K.K., Chugai Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Merck Serono Co., Ltd./Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Limited, AbbVie Inc, inVentiv Health Japan, ICON Japan K.K., GRITSONE ONCOLOGY.INC, PAREXEL International Corp., Kissei Pharmaceutical Co., Ltd., EPS Corporation, Syneos Health, Pfizer R&D Japan G.K., A2 Healthcare Corp., Quintiles Inc./IQVIA Services JAPAN K.K., EP-CRSU CO., LTD., Linical Co., Ltd., Eisai Co., Ltd., CMIC Shift Zero K.K., Kyowa Hakko Kirin Co., Ltd, Bayer Yakuhin, Ltd, EPS International Co., Ltd., Otsuka Pharmaceutical Co., Ltd. T. Honjo received a research grant from Sysmex Corporation and Ono Pharmaceutical Co. Ltd. related to this study. K. Nakagawa has received consulting fees from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Pfizer Japan Inc., Patents from Daiichi Sankyo Co., Ltd. Honoraria from Ono Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Amgen Inc., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., 3H Clinical Trial Inc., Chugai Pharmaceutical Co., Ltd., Care Net, Inc., Eli Lilly Japan K.K., Medical Review Co., Ltd., MSD K.K., Medical Mobile Communications co., Ltd, Pfizer Japan Inc., YODOSHA CO., LTD., Nippon Boehringer Ingelheim Co., Ltd., Nikkei Business Publications, Inc., Taiho Pharmaceutical Co., Ltd., Japan Clinical Research Operations Bayer Yakuhin, Ltd., CMIC Co., Ltd., CMIC ShiftZero K.K., Novartis Pharma K.K., Life Technologies Japan Ltd., TAIYO Pharma Co., Ltd., Neo Communication KYORIN Pharmaceutical Co., Ltd., Roche Diagnostics K.K., Bristol-Myers Squibb K.K., AbbVie Inc. Research Funding from PAREXEL International Corp., Eisai Co., Ltd., PRA HEALTHSCIENCES, AstraZeneca K.K., EPS Corporation, Mochida Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Covance Japan Inc., EPS International Co., Ltd., Japan Clinical Research Operations,Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., MSD K.K., Sanofi K.K., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co., Ltd., SymBio Pharmaceuticals Limited,Sysmex Corporation, IQVIA Services JAPAN K.K., Medical Research Support,SYNEOS HEALTH CLINICAL K.K., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd.,Amgen Inc., EP-CRSU Co., Ltd., Novartis Pharma K.K., Mebix, Inc., Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., SRL, Inc.,Janssen Pharmaceutical K.K.,Pfizer R&D Japan G.K., AbbVie Inc., A2 Healthcare Corp., Bayer Yakuhin, Ltd., Pfizer Japan Inc. W. Ichikawa has received honoraria from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical Co.,Ltd., Shionogi & Co., Ltd., AstraZeneca K.K., Merck Biopharma Co., Ltd., Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Nippon Kayaku Co., Ltd. All remaining authors declare no conflicts of interest.

Auteurs

Hisato Kawakami (H)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan. Electronic address: kawakami_h@med.kindai.ac.jp.

Yu Sunakawa (Y)

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.

Eisuke Inoue (E)

Showa University Research Administration Center, Showa University, Tokyo 142-8555, Japan.

Ryo Matoba (R)

DNA Chip Research Inc., Tokyo 105-0022, Japan.

Kenta Noda (K)

Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.

Toshiyuki Sato (T)

Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.

Chihiro Suminaka (C)

Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.

Mami Yamaki (M)

Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.

Yasuhiro Sakamoto (Y)

Department of Medical Oncology, Osaki Citizen Hospital, Osaki, Miyagi 989-6183, Japan.

Ryohei Kawabata (R)

Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka 591-8025, Japan.

Atsushi Ishiguro (A)

Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Hokkaido 006-8555, Japan.

Yusuke Akamaru (Y)

Department of Surgery, Ikeda City Hospital, Ikeda, Osaka 563-8510, Japan.

Yosuke Kito (Y)

Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa 920-8530, Japan.

Hiroshi Yabusaki (H)

Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Niigata 951-8566, Japan.

Jin Matsuyama (J)

Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Osaka 578-8588, Japan.

Masazumi Takahashi (M)

Division of Gastroenterological Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa 221-0855, Japan.

Akitaka Makiyama (A)

Cancer Center, Gifu University Hospital, Gifu, Gifu 501-1194, Japan.

Hidetoshi Hayashi (H)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan.

Kenji Chamoto (K)

Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8501, Japan.

Tasuku Honjo (T)

Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8501, Japan.

Kazuhiko Nakagawa (K)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan.

Wataru Ichikawa (W)

Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa 227-8501, Japan.

Masashi Fujii (M)

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Nivolumab › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Diagnostic › Pronostic › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Soluble programmed cell death ligand 1...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Soluble programmed cell death ligand 1...